The US Food and Drug Administration (FDA) has approved Dermira Inc.’s Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of excessive armpit sweating, or primary axillary hyperhidrosis, in adult and pediatric patients aged ≥9 years. About 10 million people are affected with the condition, which results in sweating beyond what is needed for regulating normal body temperature, and can affect a person’s psychological well-being and overall quality of life. Dermira Inc. is headquartered in Menlo Park, CA.
Administration: Patients should use 1 cloth to apply Qbrexza to both axillae by wiping the cloth across 1 underarm, one time. Using the same cloth, apply the medication to the other underarm, one time. Qbrexza can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes. Patients should be instructed to wash their hands with soap and water immediately after discarding the used cloth.
Adverse reactions: Most common adverse reactions (incidence ≥2%) are dry mouth, mydriasis, oropharyngeal pain, headache, urinary hesitation, vision blurred, nasal dryness, dry throat, dry eye, dry skin, and constipation. Local skin reactions, including erythema, burning/stinging, and pruritus were also common (>5%).
Dermira receives FDA approval for Qbrexza (glycopyrronium) cloth to treat primary axillary hyperhidrosis. [news release]. Menlo Park, CA: Dermira Inc. June 29, 2018. http://investor.dermira.com/phoenix.zhtml?c=253686&p=irol-newsArticle&ID=2356602. Accessed July 6, 2018.
This Week's Must Reads
Nevus Development Trajectory from Age 3 to 16 Years, JAMA Dermatology; ePub 2018 Sep 12; Asdigian, et al
Pruritis Strongly Associated with Certain Cancers , J Am Acad Dermatol; ePub 2018 Sep 11; Larson, et al
Trends in Medicare Billing Among Mohs Surgeons, Dermatolog Surg; ePub 2018 Sep 7; Tsai, et al
Mohs Surgery Effective for Invasive Melanomas, Dermatolog Surg; ePub 2018 Sep 7; Degesys, et al
Young Adults with Psoriasis Have Impaired QOL, J Dermatolog Treat; ePub 2018 Sep 7; Bronckers, et al
Must Reads in FDA Actions
FDA Approves Qbrexza for Excessive Armpit Sweating, Dermira Inc. news release; 2018 Jun 29
FDA Approves Drug Combination for Melanoma, Array BioPharma news release; 2018 Jun 27
FDA Approves Rituxan for Pemphigus Vulgaris, Genentech Web site; 2018 Jun 7
FDA Extends Label for Cimzia for Plaque Psoriasis, UCB news release; 2018 May 29
FDA Updates Label for Taltz for Genital Psoriasis, PharmaLive news release; 2018 May 22